Global RNA Interference (RNAi)-Based Therapeutics Market Growth (Status and Outlook) 2026-2032
The global RNA Interference (RNAi)-Based Therapeutics market size is predicted to grow from US$ 2498 million in 2025 to US$ 14030 million in 2032; it is expected to grow at a CAGR of 28.5% from 2026 to 2032.
The Small Interfering RNA (siRNA) Drugs Market is driven by the transformative potential of siRNA-based therapies in silencing disease-associated genes, making them a promising approach for treating a wide range of diseases, including genetic disorders, viral infections, and various cancers. siRNA drugs work by selectively degrading or inhibiting the expression of specific genes, offering a highly targeted and personalized treatment option. As the understanding of genomics and RNA interference mechanisms advances, and the need for precision medicine grows, the demand for siRNA drugs continues to rise. Innovations in siRNA design, delivery systems, and gene-editing technologies further contribute to market expansion. However, a significant challenge for this market is the need to overcome delivery barriers, ensure the stability and safety of siRNA therapeutics, and navigate regulatory complexities. Addressing off-target effects, optimizing pharmacokinetics, and managing the high cost of siRNA drug development are ongoing challenges. Additionally, the market faces competition from traditional therapeutic approaches and the need for continuous research and development to unlock the full therapeutic potential of siRNA drugs. Striking a balance between providing safe, effective, and accessible siRNA therapies while addressing scientific and regulatory challenges is essential for the continued growth of the Small Interfering RNA (siRNA) Drugs Market.
LPI (LP Information)' newest research report, the “RNA Interference (RNAi)-Based Therapeutics Industry Forecast” looks at past sales and reviews total world RNA Interference (RNAi)-Based Therapeutics sales in 2025, providing a comprehensive analysis by region and market sector of projected RNA Interference (RNAi)-Based Therapeutics sales for 2026 through 2032. With RNA Interference (RNAi)-Based Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world RNA Interference (RNAi)-Based Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global RNA Interference (RNAi)-Based Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on RNA Interference (RNAi)-Based Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global RNA Interference (RNAi)-Based Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for RNA Interference (RNAi)-Based Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global RNA Interference (RNAi)-Based Therapeutics.
This report presents a comprehensive overview, market shares, and growth opportunities of RNA Interference (RNAi)-Based Therapeutics market by product type, application, key players and key regions and countries.
Segmentation by Type:
The Small Interfering RNA (siRNA) Drugs Market is driven by the transformative potential of siRNA-based therapies in silencing disease-associated genes, making them a promising approach for treating a wide range of diseases, including genetic disorders, viral infections, and various cancers. siRNA drugs work by selectively degrading or inhibiting the expression of specific genes, offering a highly targeted and personalized treatment option. As the understanding of genomics and RNA interference mechanisms advances, and the need for precision medicine grows, the demand for siRNA drugs continues to rise. Innovations in siRNA design, delivery systems, and gene-editing technologies further contribute to market expansion. However, a significant challenge for this market is the need to overcome delivery barriers, ensure the stability and safety of siRNA therapeutics, and navigate regulatory complexities. Addressing off-target effects, optimizing pharmacokinetics, and managing the high cost of siRNA drug development are ongoing challenges. Additionally, the market faces competition from traditional therapeutic approaches and the need for continuous research and development to unlock the full therapeutic potential of siRNA drugs. Striking a balance between providing safe, effective, and accessible siRNA therapies while addressing scientific and regulatory challenges is essential for the continued growth of the Small Interfering RNA (siRNA) Drugs Market.
LPI (LP Information)' newest research report, the “RNA Interference (RNAi)-Based Therapeutics Industry Forecast” looks at past sales and reviews total world RNA Interference (RNAi)-Based Therapeutics sales in 2025, providing a comprehensive analysis by region and market sector of projected RNA Interference (RNAi)-Based Therapeutics sales for 2026 through 2032. With RNA Interference (RNAi)-Based Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world RNA Interference (RNAi)-Based Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global RNA Interference (RNAi)-Based Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on RNA Interference (RNAi)-Based Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global RNA Interference (RNAi)-Based Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for RNA Interference (RNAi)-Based Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global RNA Interference (RNAi)-Based Therapeutics.
This report presents a comprehensive overview, market shares, and growth opportunities of RNA Interference (RNAi)-Based Therapeutics market by product type, application, key players and key regions and countries.
Segmentation by Type:
- siRNA
- miRNA
- shRNA
- AHP
- hATTR
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Alnylam
- Novartis
- Sylentis
- Arrowhead
- Silence Therapeutics
- Dicerna
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global RNA Interference (RNAi)-Based Therapeutics Market Size (2021-2032)
2.1.2 RNA Interference (RNAi)-Based Therapeutics Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for RNA Interference (RNAi)-Based Therapeutics by Country/Region (2021, 2025 & 2032)
2.2 RNA Interference (RNAi)-Based Therapeutics Segment by Type
2.2.1 siRNA
2.2.2 miRNA
2.2.3 shRNA
2.2.4 RNA Interference (RNAi)-Based Therapeutics Market Size by Type
2.2.4.1 RNA Interference (RNAi)-Based Therapeutics Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.4.2 Global RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Type (2021-2026)
2.3 RNA Interference (RNAi)-Based Therapeutics Segment by Application
2.3.1 AHP
2.3.2 hATTR
2.3.3 Other
2.3.4 RNA Interference (RNAi)-Based Therapeutics Market Size by Application
2.3.4.1 RNA Interference (RNAi)-Based Therapeutics Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.4.2 Global RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Application (2021-2026)
3 RNA INTERFERENCE (RNAI)-BASED THERAPEUTICS MARKET SIZE BY PLAYER
3.1 RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Player
3.1.1 Global RNA Interference (RNAi)-Based Therapeutics Revenue by Player (2021-2026)
3.1.2 Global RNA Interference (RNAi)-Based Therapeutics Revenue Market Share by Player (2021-2026)
3.2 Global RNA Interference (RNAi)-Based Therapeutics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 RNA INTERFERENCE (RNAI)-BASED THERAPEUTICS BY REGION
4.1 RNA Interference (RNAi)-Based Therapeutics Market Size by Region (2021-2026)
4.2 Global RNA Interference (RNAi)-Based Therapeutics Annual Revenue by Country/Region (2021-2026)
4.3 Americas RNA Interference (RNAi)-Based Therapeutics Market Size Growth (2021-2026)
4.4 APAC RNA Interference (RNAi)-Based Therapeutics Market Size Growth (2021-2026)
4.5 Europe RNA Interference (RNAi)-Based Therapeutics Market Size Growth (2021-2026)
4.6 Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas RNA Interference (RNAi)-Based Therapeutics Market Size by Country (2021-2026)
5.2 Americas RNA Interference (RNAi)-Based Therapeutics Market Size by Type (2021-2026)
5.3 Americas RNA Interference (RNAi)-Based Therapeutics Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC RNA Interference (RNAi)-Based Therapeutics Market Size by Region (2021-2026)
6.2 APAC RNA Interference (RNAi)-Based Therapeutics Market Size by Type (2021-2026)
6.3 APAC RNA Interference (RNAi)-Based Therapeutics Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe RNA Interference (RNAi)-Based Therapeutics Market Size by Country (2021-2026)
7.2 Europe RNA Interference (RNAi)-Based Therapeutics Market Size by Type (2021-2026)
7.3 Europe RNA Interference (RNAi)-Based Therapeutics Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa RNA Interference (RNAi)-Based Therapeutics by Region (2021-2026)
8.2 Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Market Size by Type (2021-2026)
8.3 Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL RNA INTERFERENCE (RNAI)-BASED THERAPEUTICS MARKET FORECAST
10.1 Global RNA Interference (RNAi)-Based Therapeutics Forecast by Region (2027-2032)
10.1.1 Global RNA Interference (RNAi)-Based Therapeutics Forecast by Region (2027-2032)
10.1.2 Americas RNA Interference (RNAi)-Based Therapeutics Forecast
10.1.3 APAC RNA Interference (RNAi)-Based Therapeutics Forecast
10.1.4 Europe RNA Interference (RNAi)-Based Therapeutics Forecast
10.1.5 Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Forecast
10.2 Americas RNA Interference (RNAi)-Based Therapeutics Forecast by Country (2027-2032)
10.2.1 United States Market RNA Interference (RNAi)-Based Therapeutics Forecast
10.2.2 Canada Market RNA Interference (RNAi)-Based Therapeutics Forecast
10.2.3 Mexico Market RNA Interference (RNAi)-Based Therapeutics Forecast
10.2.4 Brazil Market RNA Interference (RNAi)-Based Therapeutics Forecast
10.3 APAC RNA Interference (RNAi)-Based Therapeutics Forecast by Region (2027-2032)
10.3.1 China RNA Interference (RNAi)-Based Therapeutics Market Forecast
10.3.2 Japan Market RNA Interference (RNAi)-Based Therapeutics Forecast
10.3.3 Korea Market RNA Interference (RNAi)-Based Therapeutics Forecast
10.3.4 Southeast Asia Market RNA Interference (RNAi)-Based Therapeutics Forecast
10.3.5 India Market RNA Interference (RNAi)-Based Therapeutics Forecast
10.3.6 Australia Market RNA Interference (RNAi)-Based Therapeutics Forecast
10.4 Europe RNA Interference (RNAi)-Based Therapeutics Forecast by Country (2027-2032)
10.4.1 Germany Market RNA Interference (RNAi)-Based Therapeutics Forecast
10.4.2 France Market RNA Interference (RNAi)-Based Therapeutics Forecast
10.4.3 UK Market RNA Interference (RNAi)-Based Therapeutics Forecast
10.4.4 Italy Market RNA Interference (RNAi)-Based Therapeutics Forecast
10.4.5 Russia Market RNA Interference (RNAi)-Based Therapeutics Forecast
10.5 Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Forecast by Region (2027-2032)
10.5.1 Egypt Market RNA Interference (RNAi)-Based Therapeutics Forecast
10.5.2 South Africa Market RNA Interference (RNAi)-Based Therapeutics Forecast
10.5.3 Israel Market RNA Interference (RNAi)-Based Therapeutics Forecast
10.5.4 Turkey Market RNA Interference (RNAi)-Based Therapeutics Forecast
10.6 Global RNA Interference (RNAi)-Based Therapeutics Forecast by Type (2027-2032)
10.7 Global RNA Interference (RNAi)-Based Therapeutics Forecast by Application (2027-2032)
10.7.1 GCC Countries Market RNA Interference (RNAi)-Based Therapeutics Forecast
11 KEY PLAYERS ANALYSIS
11.1 Alnylam
11.1.1 Alnylam Company Information
11.1.2 Alnylam RNA Interference (RNAi)-Based Therapeutics Product Offered
11.1.3 Alnylam RNA Interference (RNAi)-Based Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Alnylam Main Business Overview
11.1.5 Alnylam Latest Developments
11.2 Novartis
11.2.1 Novartis Company Information
11.2.2 Novartis RNA Interference (RNAi)-Based Therapeutics Product Offered
11.2.3 Novartis RNA Interference (RNAi)-Based Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Novartis Main Business Overview
11.2.5 Novartis Latest Developments
11.3 Sylentis
11.3.1 Sylentis Company Information
11.3.2 Sylentis RNA Interference (RNAi)-Based Therapeutics Product Offered
11.3.3 Sylentis RNA Interference (RNAi)-Based Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Sylentis Main Business Overview
11.3.5 Sylentis Latest Developments
11.4 Arrowhead
11.4.1 Arrowhead Company Information
11.4.2 Arrowhead RNA Interference (RNAi)-Based Therapeutics Product Offered
11.4.3 Arrowhead RNA Interference (RNAi)-Based Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Arrowhead Main Business Overview
11.4.5 Arrowhead Latest Developments
11.5 Silence Therapeutics
11.5.1 Silence Therapeutics Company Information
11.5.2 Silence Therapeutics RNA Interference (RNAi)-Based Therapeutics Product Offered
11.5.3 Silence Therapeutics RNA Interference (RNAi)-Based Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Silence Therapeutics Main Business Overview
11.5.5 Silence Therapeutics Latest Developments
11.6 Dicerna
11.6.1 Dicerna Company Information
11.6.2 Dicerna RNA Interference (RNAi)-Based Therapeutics Product Offered
11.6.3 Dicerna RNA Interference (RNAi)-Based Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Dicerna Main Business Overview
11.6.5 Dicerna Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global RNA Interference (RNAi)-Based Therapeutics Market Size (2021-2032)
2.1.2 RNA Interference (RNAi)-Based Therapeutics Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for RNA Interference (RNAi)-Based Therapeutics by Country/Region (2021, 2025 & 2032)
2.2 RNA Interference (RNAi)-Based Therapeutics Segment by Type
2.2.1 siRNA
2.2.2 miRNA
2.2.3 shRNA
2.2.4 RNA Interference (RNAi)-Based Therapeutics Market Size by Type
2.2.4.1 RNA Interference (RNAi)-Based Therapeutics Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.4.2 Global RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Type (2021-2026)
2.3 RNA Interference (RNAi)-Based Therapeutics Segment by Application
2.3.1 AHP
2.3.2 hATTR
2.3.3 Other
2.3.4 RNA Interference (RNAi)-Based Therapeutics Market Size by Application
2.3.4.1 RNA Interference (RNAi)-Based Therapeutics Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.4.2 Global RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Application (2021-2026)
3 RNA INTERFERENCE (RNAI)-BASED THERAPEUTICS MARKET SIZE BY PLAYER
3.1 RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Player
3.1.1 Global RNA Interference (RNAi)-Based Therapeutics Revenue by Player (2021-2026)
3.1.2 Global RNA Interference (RNAi)-Based Therapeutics Revenue Market Share by Player (2021-2026)
3.2 Global RNA Interference (RNAi)-Based Therapeutics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 RNA INTERFERENCE (RNAI)-BASED THERAPEUTICS BY REGION
4.1 RNA Interference (RNAi)-Based Therapeutics Market Size by Region (2021-2026)
4.2 Global RNA Interference (RNAi)-Based Therapeutics Annual Revenue by Country/Region (2021-2026)
4.3 Americas RNA Interference (RNAi)-Based Therapeutics Market Size Growth (2021-2026)
4.4 APAC RNA Interference (RNAi)-Based Therapeutics Market Size Growth (2021-2026)
4.5 Europe RNA Interference (RNAi)-Based Therapeutics Market Size Growth (2021-2026)
4.6 Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas RNA Interference (RNAi)-Based Therapeutics Market Size by Country (2021-2026)
5.2 Americas RNA Interference (RNAi)-Based Therapeutics Market Size by Type (2021-2026)
5.3 Americas RNA Interference (RNAi)-Based Therapeutics Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC RNA Interference (RNAi)-Based Therapeutics Market Size by Region (2021-2026)
6.2 APAC RNA Interference (RNAi)-Based Therapeutics Market Size by Type (2021-2026)
6.3 APAC RNA Interference (RNAi)-Based Therapeutics Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe RNA Interference (RNAi)-Based Therapeutics Market Size by Country (2021-2026)
7.2 Europe RNA Interference (RNAi)-Based Therapeutics Market Size by Type (2021-2026)
7.3 Europe RNA Interference (RNAi)-Based Therapeutics Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa RNA Interference (RNAi)-Based Therapeutics by Region (2021-2026)
8.2 Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Market Size by Type (2021-2026)
8.3 Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL RNA INTERFERENCE (RNAI)-BASED THERAPEUTICS MARKET FORECAST
10.1 Global RNA Interference (RNAi)-Based Therapeutics Forecast by Region (2027-2032)
10.1.1 Global RNA Interference (RNAi)-Based Therapeutics Forecast by Region (2027-2032)
10.1.2 Americas RNA Interference (RNAi)-Based Therapeutics Forecast
10.1.3 APAC RNA Interference (RNAi)-Based Therapeutics Forecast
10.1.4 Europe RNA Interference (RNAi)-Based Therapeutics Forecast
10.1.5 Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Forecast
10.2 Americas RNA Interference (RNAi)-Based Therapeutics Forecast by Country (2027-2032)
10.2.1 United States Market RNA Interference (RNAi)-Based Therapeutics Forecast
10.2.2 Canada Market RNA Interference (RNAi)-Based Therapeutics Forecast
10.2.3 Mexico Market RNA Interference (RNAi)-Based Therapeutics Forecast
10.2.4 Brazil Market RNA Interference (RNAi)-Based Therapeutics Forecast
10.3 APAC RNA Interference (RNAi)-Based Therapeutics Forecast by Region (2027-2032)
10.3.1 China RNA Interference (RNAi)-Based Therapeutics Market Forecast
10.3.2 Japan Market RNA Interference (RNAi)-Based Therapeutics Forecast
10.3.3 Korea Market RNA Interference (RNAi)-Based Therapeutics Forecast
10.3.4 Southeast Asia Market RNA Interference (RNAi)-Based Therapeutics Forecast
10.3.5 India Market RNA Interference (RNAi)-Based Therapeutics Forecast
10.3.6 Australia Market RNA Interference (RNAi)-Based Therapeutics Forecast
10.4 Europe RNA Interference (RNAi)-Based Therapeutics Forecast by Country (2027-2032)
10.4.1 Germany Market RNA Interference (RNAi)-Based Therapeutics Forecast
10.4.2 France Market RNA Interference (RNAi)-Based Therapeutics Forecast
10.4.3 UK Market RNA Interference (RNAi)-Based Therapeutics Forecast
10.4.4 Italy Market RNA Interference (RNAi)-Based Therapeutics Forecast
10.4.5 Russia Market RNA Interference (RNAi)-Based Therapeutics Forecast
10.5 Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Forecast by Region (2027-2032)
10.5.1 Egypt Market RNA Interference (RNAi)-Based Therapeutics Forecast
10.5.2 South Africa Market RNA Interference (RNAi)-Based Therapeutics Forecast
10.5.3 Israel Market RNA Interference (RNAi)-Based Therapeutics Forecast
10.5.4 Turkey Market RNA Interference (RNAi)-Based Therapeutics Forecast
10.6 Global RNA Interference (RNAi)-Based Therapeutics Forecast by Type (2027-2032)
10.7 Global RNA Interference (RNAi)-Based Therapeutics Forecast by Application (2027-2032)
10.7.1 GCC Countries Market RNA Interference (RNAi)-Based Therapeutics Forecast
11 KEY PLAYERS ANALYSIS
11.1 Alnylam
11.1.1 Alnylam Company Information
11.1.2 Alnylam RNA Interference (RNAi)-Based Therapeutics Product Offered
11.1.3 Alnylam RNA Interference (RNAi)-Based Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Alnylam Main Business Overview
11.1.5 Alnylam Latest Developments
11.2 Novartis
11.2.1 Novartis Company Information
11.2.2 Novartis RNA Interference (RNAi)-Based Therapeutics Product Offered
11.2.3 Novartis RNA Interference (RNAi)-Based Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Novartis Main Business Overview
11.2.5 Novartis Latest Developments
11.3 Sylentis
11.3.1 Sylentis Company Information
11.3.2 Sylentis RNA Interference (RNAi)-Based Therapeutics Product Offered
11.3.3 Sylentis RNA Interference (RNAi)-Based Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Sylentis Main Business Overview
11.3.5 Sylentis Latest Developments
11.4 Arrowhead
11.4.1 Arrowhead Company Information
11.4.2 Arrowhead RNA Interference (RNAi)-Based Therapeutics Product Offered
11.4.3 Arrowhead RNA Interference (RNAi)-Based Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Arrowhead Main Business Overview
11.4.5 Arrowhead Latest Developments
11.5 Silence Therapeutics
11.5.1 Silence Therapeutics Company Information
11.5.2 Silence Therapeutics RNA Interference (RNAi)-Based Therapeutics Product Offered
11.5.3 Silence Therapeutics RNA Interference (RNAi)-Based Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Silence Therapeutics Main Business Overview
11.5.5 Silence Therapeutics Latest Developments
11.6 Dicerna
11.6.1 Dicerna Company Information
11.6.2 Dicerna RNA Interference (RNAi)-Based Therapeutics Product Offered
11.6.3 Dicerna RNA Interference (RNAi)-Based Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Dicerna Main Business Overview
11.6.5 Dicerna Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. RNA Interference (RNAi)-Based Therapeutics Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. RNA Interference (RNAi)-Based Therapeutics Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of siRNA
Table 4. Major Players of miRNA
Table 5. Major Players of shRNA
Table 6. RNA Interference (RNAi)-Based Therapeutics Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 7. Global RNA Interference (RNAi)-Based Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 8. Global RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Type (2021-2026)
Table 9. RNA Interference (RNAi)-Based Therapeutics Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 10. Global RNA Interference (RNAi)-Based Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 11. Global RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Application (2021-2026)
Table 12. Global RNA Interference (RNAi)-Based Therapeutics Revenue by Player (2021-2026) & ($ millions)
Table 13. Global RNA Interference (RNAi)-Based Therapeutics Revenue Market Share by Player (2021-2026)
Table 14. RNA Interference (RNAi)-Based Therapeutics Key Players Head office and Products Offered
Table 15. RNA Interference (RNAi)-Based Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global RNA Interference (RNAi)-Based Therapeutics Market Size by Region (2021-2026) & ($ millions)
Table 19. Global RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Region (2021-2026)
Table 20. Global RNA Interference (RNAi)-Based Therapeutics Revenue by Country/Region (2021-2026) & ($ millions)
Table 21. Global RNA Interference (RNAi)-Based Therapeutics Revenue Market Share by Country/Region (2021-2026)
Table 22. Americas RNA Interference (RNAi)-Based Therapeutics Market Size by Country (2021-2026) & ($ millions)
Table 23. Americas RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Country (2021-2026)
Table 24. Americas RNA Interference (RNAi)-Based Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 25. Americas RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Type (2021-2026)
Table 26. Americas RNA Interference (RNAi)-Based Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 27. Americas RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Application (2021-2026)
Table 28. APAC RNA Interference (RNAi)-Based Therapeutics Market Size by Region (2021-2026) & ($ millions)
Table 29. APAC RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Region (2021-2026)
Table 30. APAC RNA Interference (RNAi)-Based Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 31. APAC RNA Interference (RNAi)-Based Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 32. Europe RNA Interference (RNAi)-Based Therapeutics Market Size by Country (2021-2026) & ($ millions)
Table 33. Europe RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Country (2021-2026)
Table 34. Europe RNA Interference (RNAi)-Based Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 35. Europe RNA Interference (RNAi)-Based Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 36. Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Market Size by Region (2021-2026) & ($ millions)
Table 37. Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 38. Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 39. Key Market Drivers & Growth Opportunities of RNA Interference (RNAi)-Based Therapeutics
Table 40. Key Market Challenges & Risks of RNA Interference (RNAi)-Based Therapeutics
Table 41. Key Industry Trends of RNA Interference (RNAi)-Based Therapeutics
Table 42. Global RNA Interference (RNAi)-Based Therapeutics Market Size Forecast by Region (2027-2032) & ($ millions)
Table 43. Global RNA Interference (RNAi)-Based Therapeutics Market Size Market Share Forecast by Region (2027-2032)
Table 44. Global RNA Interference (RNAi)-Based Therapeutics Market Size Forecast by Type (2027-2032) & ($ millions)
Table 45. Global RNA Interference (RNAi)-Based Therapeutics Market Size Forecast by Application (2027-2032) & ($ millions)
Table 46. Alnylam Details, Company Type, RNA Interference (RNAi)-Based Therapeutics Area Served and Its Competitors
Table 47. Alnylam RNA Interference (RNAi)-Based Therapeutics Product Offered
Table 48. Alnylam RNA Interference (RNAi)-Based Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 49. Alnylam Main Business
Table 50. Alnylam Latest Developments
Table 51. Novartis Details, Company Type, RNA Interference (RNAi)-Based Therapeutics Area Served and Its Competitors
Table 52. Novartis RNA Interference (RNAi)-Based Therapeutics Product Offered
Table 53. Novartis RNA Interference (RNAi)-Based Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 54. Novartis Main Business
Table 55. Novartis Latest Developments
Table 56. Sylentis Details, Company Type, RNA Interference (RNAi)-Based Therapeutics Area Served and Its Competitors
Table 57. Sylentis RNA Interference (RNAi)-Based Therapeutics Product Offered
Table 58. Sylentis RNA Interference (RNAi)-Based Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 59. Sylentis Main Business
Table 60. Sylentis Latest Developments
Table 61. Arrowhead Details, Company Type, RNA Interference (RNAi)-Based Therapeutics Area Served and Its Competitors
Table 62. Arrowhead RNA Interference (RNAi)-Based Therapeutics Product Offered
Table 63. Arrowhead RNA Interference (RNAi)-Based Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 64. Arrowhead Main Business
Table 65. Arrowhead Latest Developments
Table 66. Silence Therapeutics Details, Company Type, RNA Interference (RNAi)-Based Therapeutics Area Served and Its Competitors
Table 67. Silence Therapeutics RNA Interference (RNAi)-Based Therapeutics Product Offered
Table 68. Silence Therapeutics RNA Interference (RNAi)-Based Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 69. Silence Therapeutics Main Business
Table 70. Silence Therapeutics Latest Developments
Table 71. Dicerna Details, Company Type, RNA Interference (RNAi)-Based Therapeutics Area Served and Its Competitors
Table 72. Dicerna RNA Interference (RNAi)-Based Therapeutics Product Offered
Table 73. Dicerna RNA Interference (RNAi)-Based Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 74. Dicerna Main Business
Table 75. Dicerna Latest Developments
Table 1. RNA Interference (RNAi)-Based Therapeutics Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. RNA Interference (RNAi)-Based Therapeutics Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of siRNA
Table 4. Major Players of miRNA
Table 5. Major Players of shRNA
Table 6. RNA Interference (RNAi)-Based Therapeutics Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 7. Global RNA Interference (RNAi)-Based Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 8. Global RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Type (2021-2026)
Table 9. RNA Interference (RNAi)-Based Therapeutics Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 10. Global RNA Interference (RNAi)-Based Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 11. Global RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Application (2021-2026)
Table 12. Global RNA Interference (RNAi)-Based Therapeutics Revenue by Player (2021-2026) & ($ millions)
Table 13. Global RNA Interference (RNAi)-Based Therapeutics Revenue Market Share by Player (2021-2026)
Table 14. RNA Interference (RNAi)-Based Therapeutics Key Players Head office and Products Offered
Table 15. RNA Interference (RNAi)-Based Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global RNA Interference (RNAi)-Based Therapeutics Market Size by Region (2021-2026) & ($ millions)
Table 19. Global RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Region (2021-2026)
Table 20. Global RNA Interference (RNAi)-Based Therapeutics Revenue by Country/Region (2021-2026) & ($ millions)
Table 21. Global RNA Interference (RNAi)-Based Therapeutics Revenue Market Share by Country/Region (2021-2026)
Table 22. Americas RNA Interference (RNAi)-Based Therapeutics Market Size by Country (2021-2026) & ($ millions)
Table 23. Americas RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Country (2021-2026)
Table 24. Americas RNA Interference (RNAi)-Based Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 25. Americas RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Type (2021-2026)
Table 26. Americas RNA Interference (RNAi)-Based Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 27. Americas RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Application (2021-2026)
Table 28. APAC RNA Interference (RNAi)-Based Therapeutics Market Size by Region (2021-2026) & ($ millions)
Table 29. APAC RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Region (2021-2026)
Table 30. APAC RNA Interference (RNAi)-Based Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 31. APAC RNA Interference (RNAi)-Based Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 32. Europe RNA Interference (RNAi)-Based Therapeutics Market Size by Country (2021-2026) & ($ millions)
Table 33. Europe RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Country (2021-2026)
Table 34. Europe RNA Interference (RNAi)-Based Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 35. Europe RNA Interference (RNAi)-Based Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 36. Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Market Size by Region (2021-2026) & ($ millions)
Table 37. Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Market Size by Type (2021-2026) & ($ millions)
Table 38. Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Market Size by Application (2021-2026) & ($ millions)
Table 39. Key Market Drivers & Growth Opportunities of RNA Interference (RNAi)-Based Therapeutics
Table 40. Key Market Challenges & Risks of RNA Interference (RNAi)-Based Therapeutics
Table 41. Key Industry Trends of RNA Interference (RNAi)-Based Therapeutics
Table 42. Global RNA Interference (RNAi)-Based Therapeutics Market Size Forecast by Region (2027-2032) & ($ millions)
Table 43. Global RNA Interference (RNAi)-Based Therapeutics Market Size Market Share Forecast by Region (2027-2032)
Table 44. Global RNA Interference (RNAi)-Based Therapeutics Market Size Forecast by Type (2027-2032) & ($ millions)
Table 45. Global RNA Interference (RNAi)-Based Therapeutics Market Size Forecast by Application (2027-2032) & ($ millions)
Table 46. Alnylam Details, Company Type, RNA Interference (RNAi)-Based Therapeutics Area Served and Its Competitors
Table 47. Alnylam RNA Interference (RNAi)-Based Therapeutics Product Offered
Table 48. Alnylam RNA Interference (RNAi)-Based Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 49. Alnylam Main Business
Table 50. Alnylam Latest Developments
Table 51. Novartis Details, Company Type, RNA Interference (RNAi)-Based Therapeutics Area Served and Its Competitors
Table 52. Novartis RNA Interference (RNAi)-Based Therapeutics Product Offered
Table 53. Novartis RNA Interference (RNAi)-Based Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 54. Novartis Main Business
Table 55. Novartis Latest Developments
Table 56. Sylentis Details, Company Type, RNA Interference (RNAi)-Based Therapeutics Area Served and Its Competitors
Table 57. Sylentis RNA Interference (RNAi)-Based Therapeutics Product Offered
Table 58. Sylentis RNA Interference (RNAi)-Based Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 59. Sylentis Main Business
Table 60. Sylentis Latest Developments
Table 61. Arrowhead Details, Company Type, RNA Interference (RNAi)-Based Therapeutics Area Served and Its Competitors
Table 62. Arrowhead RNA Interference (RNAi)-Based Therapeutics Product Offered
Table 63. Arrowhead RNA Interference (RNAi)-Based Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 64. Arrowhead Main Business
Table 65. Arrowhead Latest Developments
Table 66. Silence Therapeutics Details, Company Type, RNA Interference (RNAi)-Based Therapeutics Area Served and Its Competitors
Table 67. Silence Therapeutics RNA Interference (RNAi)-Based Therapeutics Product Offered
Table 68. Silence Therapeutics RNA Interference (RNAi)-Based Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 69. Silence Therapeutics Main Business
Table 70. Silence Therapeutics Latest Developments
Table 71. Dicerna Details, Company Type, RNA Interference (RNAi)-Based Therapeutics Area Served and Its Competitors
Table 72. Dicerna RNA Interference (RNAi)-Based Therapeutics Product Offered
Table 73. Dicerna RNA Interference (RNAi)-Based Therapeutics Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 74. Dicerna Main Business
Table 75. Dicerna Latest Developments
LIST OF FIGURES
Figure 1. RNA Interference (RNAi)-Based Therapeutics Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global RNA Interference (RNAi)-Based Therapeutics Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. RNA Interference (RNAi)-Based Therapeutics Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. RNA Interference (RNAi)-Based Therapeutics Sales Market Share by Country/Region (2025)
Figure 8. RNA Interference (RNAi)-Based Therapeutics Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Type in 2025
Figure 10. RNA Interference (RNAi)-Based Therapeutics in AHP
Figure 11. Global RNA Interference (RNAi)-Based Therapeutics Market: AHP (2021-2026) & ($ millions)
Figure 12. RNA Interference (RNAi)-Based Therapeutics in hATTR
Figure 13. Global RNA Interference (RNAi)-Based Therapeutics Market: hATTR (2021-2026) & ($ millions)
Figure 14. RNA Interference (RNAi)-Based Therapeutics in Other
Figure 15. Global RNA Interference (RNAi)-Based Therapeutics Market: Other (2021-2026) & ($ millions)
Figure 16. Global RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Application in 2025
Figure 17. Global RNA Interference (RNAi)-Based Therapeutics Revenue Market Share by Player in 2025
Figure 18. Global RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Region (2021-2026)
Figure 19. Americas RNA Interference (RNAi)-Based Therapeutics Market Size 2021-2026 ($ millions)
Figure 20. APAC RNA Interference (RNAi)-Based Therapeutics Market Size 2021-2026 ($ millions)
Figure 21. Europe RNA Interference (RNAi)-Based Therapeutics Market Size 2021-2026 ($ millions)
Figure 22. Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Market Size 2021-2026 ($ millions)
Figure 23. Americas RNA Interference (RNAi)-Based Therapeutics Value Market Share by Country in 2025
Figure 24. United States RNA Interference (RNAi)-Based Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 25. Canada RNA Interference (RNAi)-Based Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 26. Mexico RNA Interference (RNAi)-Based Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 27. Brazil RNA Interference (RNAi)-Based Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 28. APAC RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Region in 2025
Figure 29. APAC RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Type (2021-2026)
Figure 30. APAC RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Application (2021-2026)
Figure 31. China RNA Interference (RNAi)-Based Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 32. Japan RNA Interference (RNAi)-Based Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 33. South Korea RNA Interference (RNAi)-Based Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 34. Southeast Asia RNA Interference (RNAi)-Based Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 35. India RNA Interference (RNAi)-Based Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 36. Australia RNA Interference (RNAi)-Based Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 37. Europe RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Country in 2025
Figure 38. Europe RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Type (2021-2026)
Figure 39. Europe RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Application (2021-2026)
Figure 40. Germany RNA Interference (RNAi)-Based Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 41. France RNA Interference (RNAi)-Based Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 42. UK RNA Interference (RNAi)-Based Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 43. Italy RNA Interference (RNAi)-Based Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 44. Russia RNA Interference (RNAi)-Based Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 45. Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Region (2021-2026)
Figure 46. Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Type (2021-2026)
Figure 47. Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Application (2021-2026)
Figure 48. Egypt RNA Interference (RNAi)-Based Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 49. South Africa RNA Interference (RNAi)-Based Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 50. Israel RNA Interference (RNAi)-Based Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 51. Turkey RNA Interference (RNAi)-Based Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 52. GCC Countries RNA Interference (RNAi)-Based Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 53. Americas RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 54. APAC RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 55. Europe RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 56. Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 57. United States RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 58. Canada RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 59. Mexico RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 60. Brazil RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 61. China RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 62. Japan RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 63. Korea RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 64. Southeast Asia RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 65. India RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 66. Australia RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 67. Germany RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 68. France RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 69. UK RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 70. Italy RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 71. Russia RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 72. Egypt RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 73. South Africa RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 74. Israel RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 75. Turkey RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 76. Global RNA Interference (RNAi)-Based Therapeutics Market Size Market Share Forecast by Type (2027-2032)
Figure 77. Global RNA Interference (RNAi)-Based Therapeutics Market Size Market Share Forecast by Application (2027-2032)
Figure 78. GCC Countries RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 1. RNA Interference (RNAi)-Based Therapeutics Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global RNA Interference (RNAi)-Based Therapeutics Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. RNA Interference (RNAi)-Based Therapeutics Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. RNA Interference (RNAi)-Based Therapeutics Sales Market Share by Country/Region (2025)
Figure 8. RNA Interference (RNAi)-Based Therapeutics Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Type in 2025
Figure 10. RNA Interference (RNAi)-Based Therapeutics in AHP
Figure 11. Global RNA Interference (RNAi)-Based Therapeutics Market: AHP (2021-2026) & ($ millions)
Figure 12. RNA Interference (RNAi)-Based Therapeutics in hATTR
Figure 13. Global RNA Interference (RNAi)-Based Therapeutics Market: hATTR (2021-2026) & ($ millions)
Figure 14. RNA Interference (RNAi)-Based Therapeutics in Other
Figure 15. Global RNA Interference (RNAi)-Based Therapeutics Market: Other (2021-2026) & ($ millions)
Figure 16. Global RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Application in 2025
Figure 17. Global RNA Interference (RNAi)-Based Therapeutics Revenue Market Share by Player in 2025
Figure 18. Global RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Region (2021-2026)
Figure 19. Americas RNA Interference (RNAi)-Based Therapeutics Market Size 2021-2026 ($ millions)
Figure 20. APAC RNA Interference (RNAi)-Based Therapeutics Market Size 2021-2026 ($ millions)
Figure 21. Europe RNA Interference (RNAi)-Based Therapeutics Market Size 2021-2026 ($ millions)
Figure 22. Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Market Size 2021-2026 ($ millions)
Figure 23. Americas RNA Interference (RNAi)-Based Therapeutics Value Market Share by Country in 2025
Figure 24. United States RNA Interference (RNAi)-Based Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 25. Canada RNA Interference (RNAi)-Based Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 26. Mexico RNA Interference (RNAi)-Based Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 27. Brazil RNA Interference (RNAi)-Based Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 28. APAC RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Region in 2025
Figure 29. APAC RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Type (2021-2026)
Figure 30. APAC RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Application (2021-2026)
Figure 31. China RNA Interference (RNAi)-Based Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 32. Japan RNA Interference (RNAi)-Based Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 33. South Korea RNA Interference (RNAi)-Based Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 34. Southeast Asia RNA Interference (RNAi)-Based Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 35. India RNA Interference (RNAi)-Based Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 36. Australia RNA Interference (RNAi)-Based Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 37. Europe RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Country in 2025
Figure 38. Europe RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Type (2021-2026)
Figure 39. Europe RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Application (2021-2026)
Figure 40. Germany RNA Interference (RNAi)-Based Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 41. France RNA Interference (RNAi)-Based Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 42. UK RNA Interference (RNAi)-Based Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 43. Italy RNA Interference (RNAi)-Based Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 44. Russia RNA Interference (RNAi)-Based Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 45. Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Region (2021-2026)
Figure 46. Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Type (2021-2026)
Figure 47. Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Market Size Market Share by Application (2021-2026)
Figure 48. Egypt RNA Interference (RNAi)-Based Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 49. South Africa RNA Interference (RNAi)-Based Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 50. Israel RNA Interference (RNAi)-Based Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 51. Turkey RNA Interference (RNAi)-Based Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 52. GCC Countries RNA Interference (RNAi)-Based Therapeutics Market Size Growth 2021-2026 ($ millions)
Figure 53. Americas RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 54. APAC RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 55. Europe RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 56. Middle East & Africa RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 57. United States RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 58. Canada RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 59. Mexico RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 60. Brazil RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 61. China RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 62. Japan RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 63. Korea RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 64. Southeast Asia RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 65. India RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 66. Australia RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 67. Germany RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 68. France RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 69. UK RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 70. Italy RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 71. Russia RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 72. Egypt RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 73. South Africa RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 74. Israel RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 75. Turkey RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
Figure 76. Global RNA Interference (RNAi)-Based Therapeutics Market Size Market Share Forecast by Type (2027-2032)
Figure 77. Global RNA Interference (RNAi)-Based Therapeutics Market Size Market Share Forecast by Application (2027-2032)
Figure 78. GCC Countries RNA Interference (RNAi)-Based Therapeutics Market Size 2027-2032 ($ millions)
